Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

White House Reassures Abortion-Rights Advocates Of Sotomayor's Views On Roe
White House Press Secretary Robert Gibbs on Thursday assured abortion-rights groups that Supreme Court nominee Judge Sonia Sotomayor shares President Obama"s views on constitutional protection for a right to privacy and a woman"s right to abortion, the Washington Post reports. Although many abortion-rights groups have welcomed the nomination, some have voiced concern over Sotomayor"s limited judicial record on cases involving abortion rights, especially the right to privacy that forms the basis for Roe v. Wade. Gibbs said that although Obama did not specifically ask Sotomayor about abortion rights during preliminary interviews, the White House is certain she agrees with the president on the constitutionality of Roe. Obama and Sotomayor "talked about the theory of constitutional interpretation, generally, including her views on unenumerated rights in the Constitution and the theory of settled law," Gibbs said, adding that Obama felt "very comfortable with her interpretation of the Constitution being similar to that of his." In a 2007 campaign debate, Obama said he would not nominate "somebody who doesn"t believe in the right to privacy," which the Supreme Court ruled gave women the right to terminate a pregnancy. Obama administration officials also said that they held private conversations on Thursday with groups on both sides of the abortion debate.The Post reports that Sotomayor has not dealt with constitutional issues regarding abortion rights in the nearly two decades she has been a federal judge. Her most notable decision regarding abortion was in 2002 when she ruled that the Bush administration had the right to implement the "global gag rule," which banned federal funding for international family planning groups that offer abortion services and information. Although that decision "reveals nothing about abortion rights," it is based on precedents from the Supreme Court and the Second U.S. Circuit of Appeals, the Post reports. Sotomayor wrote in her decision that the Supreme Court "has made clear that the government is free to favor the antiabortion position over the pro-choice position, and can do so with public funds." She also ruled that a group of antiabortion-rights protesters could go forward with a lawsuit alleging police brutality; however, that case focused on issues of municipal liability, not the constitutional right to an abortion, according to the Post.Currently, the court is essentially split on the issue of the right to privacy and abortion. Retiring Justice David Souter was one of three authors in a 2002 decision that upheld the basic tenets Roe, and abortion-rights supporters believe that replacing Souter with someone who does not support Roe would threaten those rights, the Post reports. Senior Senate Democrats said that they expect the issue to be brought up during private meetings with Sotomayor next week. However, Sen. Barbara Boxer (D-Calif.), a strong supporter of abortion rights, said she will not specifically ask Sotomayor about Roe. She said that she "feel[s] as comfortable as I could possibly feel" about Sotomayor"s support for abortion rights (Barnes/Shear, Washington Post, 5/29). Advocates on both sides of the abortion-rights debate are urging members of the Senate Judiciary Committee to question Sotomayor about her views during her confirmation hearings. Nancy Northup of the Center for Reproductive Rights said, "I think both sides can agree that the American people should know where its nominees to the Supreme Court stand on important constitutionally decided decisions like Roe v. Wade." Charmaine Yoest, president of Americans United for Life, said, "We"ve really been focused on asking senators to really probe this question of her judicial philosophy, as to whether or not she"s going to approach a decision like [Roe] as a jurist or as a woman" (Totenberg, "All Things Considered," NPR, 5/28). Douglas Johnson, legislative director of the National Right to Life Committee, said his group thinks it is "critical that senators thoroughly explore whether [Sotomayor] b
generic viagra online
Argenta Discovery And Porsolt Join Forces To Provide Fully-integrated CNS And Pain Contract Drug Discovery Services
Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of "Big Pharma" industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates.
News of the day
Study Challenges Routine Use Of MRI Scans To Evaluate Breast Cancer
Reviewing the records of 577 breast cancer patients, Fox Chase Cancer Center researchers found that women with newly diagnosed breast cancer who receive a breast MRI are more likely to receive a mastectomy after their diagnosis and may face delays in starting treatment. The study demonstrates that, despite the lack of evidence of their benefit, routine use of MRI scans in women newly diagnosed with breast cancer increased significantly between 2004 and 2005, and again in 2006.
Endocrinology

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received a second orphan drug designation in the US only weeks after a first designation was granted. The recent designation relates to Burkholderia cepacia pathogens that can cause lethal infections in cystic fibrosis patients. For Axentis Pharma AG of Zurich, Switzerland, both designations affirm the therapeutic potential of its product candidate Fluidosomes(TM)-tobramycin, whose unique microbiological profile sets it apart from other antibiotic formulations (including free tobramycin). Axentis Pharma (Switzerland) announced that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted a second orphan drug designation to its lead product candidate Fluidosomes(TM)-tobramycin. This drug is a liposomal formulation of tobramycin and an innovative treatment for infections of the respiratory tract in patients with cystic fibrosis. Only three months ago, the FDA granted Fluidosomes(TM)-tobramycin orphan drug designation for the treatment of pulmonary infections caused by Pseudomonas aeruginosa. The newly granted second designation relates to pulmonary infections caused by Burkholderia cepacia (B. cepacia) pathogens. Despite stringent infection control practices, B. cepacia infections still occur in cystic fibrosis patients and can lead to fatal sepsis. The cell envelopes of these especially virulent bacteria are impermeable to most antibiotics, which makes them particularly difficult to treat. Due to its unique mode of action, which allows the antibiotics to penetrate into the bacteria, Fluidosomes(TM)-tobramycin could become a particularly effective treatment for B. cepacia infections. Prof. Dr. Miguel A Valvano, MD, Medical Advisor to Axentis Pharma, comments on the development: "Burkholderia cepacia is almost always multi-resistant to antibiotics and this, in conjunction with the poor prognosis of patients with B. cepacia infection, makes the treatment of these patients exceedingly complex. Tobramycin is in principle an effective antibiotic. The drug is however rather ineffective due to the impermeability of B. cepacia"s cell envelope. In addition, B. cepacia - just like many other pathogens - has developed mechanisms to eliminate antibiotics once they have entered the cell. Fluidosomes(TM)-tobramycin seems to overcome these limitations by packing tobramycin into liposomes, which, by allowing effective penetration of the antibiotic into the bacterial cell, completely changes the microbiological profile of this antibiotic. Hence, Fluidosomes(TM)-tobramycin could be a totally new antibiotic formulation that addresses microbiological needs that no other antibiotic can." What exactly happens when Fluidosomes(TM)-tobramycin encounters the bacterium is still not entirely clear, but pre-clinical data indicate a novel mode of action. Dr. Helmut Brunar, CEO of Axentis Pharma explains: "Once at the site of infection, tobramycin-containing liposomes seem to fuse with the cell membrane of the pathogen. In this way, the entire load of tobramycin contained in the Fluidosomes(TM) is released into the bacterial cell. Additionally, our data indicate that bacterial rescue mechanisms that pump tobramycin out of the cell are inhibited by the fusion process. The efficient delivery and maximum release of tobramycin into the bacterial cell together with inhibition of the clearance mechanism indicate that Fluidosomes(TM)-tobramycin has a highly efficient therapeutic effect." About Axentis Pharma AG Axentis Pharma is a respiratory specialty pharmaceutical company whose core competence is the combination of a fully patented, liposome-based drug delivery system with already established and well-characterized therapeutic agents. The company is using its platform delivery technology, named Fluidosomes(TM) technology, for the development of its lead product, an inhalable liposomal formulation of tobramycin. Axentis Pharma"s lead product is designed to treat bacterial infections in the lungs. About Fluidosomes(TM) technology Axentis Pharma"s Fluidosomes(TM) technology uses biocompatible lipids endogenous to the lung that are formulated into small liposomes. This nanocapsule platform offers wide-ranging potential for unmet medical needs, including chronic respiratory infections of the lung. In the case of Fluidosomes(TM)-tobramycin, the interaction between tobramycin and the microbial cell is triggered when the liposomes undergo a fusion process with the outer membrane of the bacterial cell wall. Tobramycin then penetrates into the inner cell compartment and triggers bacterial cell death. Axentis Pharma AG


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009